Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$85.98 USD
-0.42 (-0.49%)
Updated May 28, 2024 04:00 PM ET
After-Market: $86.05 +0.07 (0.08%) 6:20 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 21 - 40 ( 717 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Important Execution a Year Later; Analyst Day Highlights Strong Growth Positioning
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Increased Investment in QTORIN Should Drive Added Cash Flow
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for LGND 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
3Q23 Results; Continued Shopping, Streamlining and Royalty Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
New Royalty to Hit Immediately; Thesis Keeps Plugging Away; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Investments Across Different Need Spectrums; Ligand Buys 13% Interest in Soticlestat
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Ligand Acquires Novan Assets, Offering Future Financial Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department